Loading patent…
AssigneeEli Lilly and Company
InventorsThomas F. Bumol, Robert A. Gadski, Amy E. Hamilton, J. Richard Sportsiman, Joann Strnad
Estimating the term…
The present invention comprises novel recombinant DNA compounds which encode the .about.40,000 dalton adenocarcinoma antigen recognized by monoclonal antibody KS 1/4. Eukaryotic and prokaryotic expression vectors have been constructed that comprise novel KSA-encoding DNA and drive expression of KSA when transformed into an appropriate host cell. The novel expression vectors can be used to produce KSA derivatives, such as non-glycosylated KSA, and to produce KSA precursors, such as nascent KSA, and to produce subfragments of KSA. The recombinant-produced KSA is useful for the diagnosis, prognosis and treatment of disease states including adenocarcinomas of the lung, prostate, breast, ovary and colon/rectum; and for the creation of novel antibodies for treatment or diagnosis of the above.
A recombinant DNA encoding mature KSA wherein the coding strand is:
A recombinant DNA encoding pro KSA wherein the coding strand is:
A recombinant DNA encoding prepro KSA herein the coding strand is:
A recombinant DNA expression vector that is plasmid pLKSA.
A recombinant DNA vector selected from the group consisting of plasmids pAG932, pAG1338 and pLKSA-B.
Dependencies are inferred from the claim text.